Under the terms of the deal, GIC, one of the world’s biggest institutional investors, and healthcare-focused private equity group Linden Capital Partners will buy out a minority stake owned by rival ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies.